LabPMM® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials
Article content
SAN DIEGO — Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine ® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe's ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide.
Article content
The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases, 1 stable over time, 2 and, if present in blood at allele fractions ≥0.01%, are associated with increased relapse and worse overall survival. 3 Recent studies show emerging evidence that pre-transplant MRD testing for NPM1 and FLT3 -ITD identifies AML patients in remission who are most likely to relapse or experience poor survival. 3,4,5 With this approval, LabPMM is helping to transform the landscape of AML research, treatment and drug development. By using MRD as a surrogate endpoint in clinical trials, instead of relying solely on overall survival (OS), pharmaceutical companies can accelerate their drug development timelines. This is particularly valuable in acute disease, where time is of the essence, and earlier intervention can dramatically improve patient outcomes.
Article content
'We are proud to receive New York State approval for our NPM1 MRD Assay by NGS, marking our second assay approved by New York State this year,' said Jordan Thornes, V.P., Global Clinical Laboratory Operations at LabPMM. 'This milestone reflects our continued dedication to advancing precision diagnostics in cancer care. With this latest approval, we're further empowering clinicians with sensitive, reliable tools to detect residual disease and guide treatment decisions with confidence.'
Article content
LabPMM's NPM1 and FLT3 ITD MRD Assays are standardized next generation sequencing (NGS) tests that complement the LeukoStrat ® CDx FLT3 Mutation Assay, which is used to guide treatment selection for patients with AML. These services are offered in the U.S., European Union, and across Asia to ensure patients around the world have access to high-quality, standardized testing and to support the development of cutting-edge cancer treatments. LabPMM remains committed to advancing precision medicine and improving outcomes for patients worldwide. For more information about the NPM1 MRD Assay and LabPMM's full test menu, please visit https://invivoscribe.com/clinical-lab-services/ or contact us at inquiry@invivoscribe.com and follow us on LinkedIn.
Article content
About Invivoscribe
Article content
Invivoscribe ® is a global, vertically integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics ®. For thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, and bioinformatics tools to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with pharmaceutical companies interested in clinical trial testing via our global lab network located in the U.S., Germany, Japan and China, and in developing and commercializing companion diagnostics, with our rigorous expertise in both regulatory and laboratory services. Providing distributable kits, as well as clinical trial services through its globally located clinical lab subsidiaries (LabPMM ®), Invivoscribe is an ideal partner from diagnostic development, through clinical trials, regulatory submissions, and commercialization.
Article content
Article content
Article content
Article content
Article content
Article content
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Ibogaine by David Dardashti Forges Strategic Partnership with Psychedelic University to Cultivate Next-Generation Leaders in Psychedelic Healthcare
MIAMI, FL - June 20, 2025 - Ibogaine by David Dardashti, a pioneering leader in ibogaine-assisted therapy and led by visionary David Dardashti, today announced a groundbreaking collaboration with a Psychedelic University. This strategic partnership aims to establish robust internship opportunities for students passionate about contributing to the rapidly evolving psychedelic field, with initial networking prospects to be explored at the highly anticipated Psychedelic Conference 2025. The initiative is further amplified by the recent opening of Ibogaine by David Dardashti's second state-of-the-art treatment facility, significantly expanding the scope for student involvement. This innovative alliance is designed to bridge the gap between academic learning and practical application, providing students with invaluable hands-on experience in a clinical setting dedicated to transformative healing. The expansion into a second facility dramatically increases Ibogaine by David Dardashti's capacity, creating a diverse array of potential roles for aspiring professionals. "We are incredibly excited to partner with Psychedelic University to nurture the next generation of leaders in psychedelic medicine," said David Dardashti, founder of Ibogaine by David Dardashti. "The opening of our second clinic is not just about expanding our treatment capabilities; it's about building a robust ecosystem where ambitious students can gain real-world experience and help accelerate the growth and acceptance of ibogaine therapy. We believe this collaboration will foster innovation and ethical practices crucial for the future of this field." The internship program will offer multifaceted opportunities for students from various disciplines. Beyond direct clinical exposure, students can expect to engage in critical areas such as: Therapy Options: Assisting in the development and delivery of integrative post-treatment care plans, including counseling and psychological support. Data Collection & Analysis: Contributing to the meticulous gathering and interpretation of patient outcomes, vital for advancing research and validating treatment efficacy. Biomedical Software Development: Participating in the creation and refinement of digital tools designed to enhance patient management, treatment protocols, and research analytics. Marketing Solutions: Developing strategic communication plans to educate the public, destigmatize ibogaine, and expand access to treatment. Meetings will be held in the months following a patient's treatment, creating a unique longitudinal learning environment where interns can observe the full spectrum of patient journeys and recovery. This comprehensive approach ensures that students gain a holistic understanding of patient care, from initial intake to long-term integration support. Representatives from both Ibogaine by David Dardashti and Psychedelic University will be actively engaging with students at the Psychedelic Conference 2025, providing a premier platform for aspiring interns to learn more about these opportunities and network with pioneers in the field. This direct interaction will allow students to present their aspirations and demonstrate their commitment to this burgeoning area of healthcare. The ultimate goal of Ibogaine by David Dardashti is to expand its new clinic with the support of ambitious, dedicated students who are eager to contribute to accelerating the growth and responsible application of ibogaine treatment. This partnership underscores a shared commitment to innovation, education, and the widespread, ethical integration of psychedelic therapies into mainstream healthcare.
CTV News
4 hours ago
- CTV News
Older adults dying from unintentional falls
Older adults dying from unintentional falls A new report shows older adults are dying more from unintentional falls leads MedicalWatch for June 19, 2025.
Globe and Mail
5 hours ago
- Globe and Mail
Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?
Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology or cancer is one of the most sought-after areas in the pharma/biotech space. As the world at large continues to grapple with a significant increase in the number of cancer patients, the market for cancer medicines is expected to grow. Pfizer is one of the largest and most successful drugmakers in the field of oncology. Oncology sales comprise around 25% of its total revenues. Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. Both drugmakers have strong footholds in their respective target markets, delivering consistent returns to shareholders. In such a scenario, choosing one stock over another can be challenging. Let us delve into their fundamentals, potential growth prospects, challenges and valuation levels to make a prudent choice. The Case for Pfizer Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Approved drugs in the portfolio include Ibrance, Xtandi, Inlyta, Lorbrena, Bosulif, Braftovi, Mektovi, Orgovyx, Elrexfio and Talzenna. Among these, the breast cancer drug Ibrance is one of the top revenue generators. The acquisition of Seagen in December 2023 strengthened PFE's oncology portfolio by adding four ADCs — Adcetris, Padcev, Tukysa and Tivdak. This initiative boosted oncology sales in 2024 and the first quarter of 2025. Seagen also has some next-generation ADC candidates in its pipeline and their successful development should further strengthen its portfolio. PFE is working on the label expansion of many of its cancer drugs that should boost sales. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. Oncology biosimilars primarily include Retacrit, Ruxience, Zirabev, Trazimera and Nivestym. Pfizer is also advancing a robust pipeline of oncology candidates, with several entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio. Apart from oncology, Pfizer's portfolio has a variety of drugs and vaccines for diseases like COVID-19, inflammation & immunology diseases, rare diseases and migraine, among others. The Case for Bristol Myers BMY is focused on extending and strengthening its leadership in immuno-oncology (IO), as well as diversifying beyond IO. Leading IO drug Opdivo, approved for several cancer indications, drives its oncology franchise along with Yervoy and Opdualag. The FDA recently granted approval to Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for subcutaneous use. Per BMY, this new subcutaneous formulation of Opdivo should help extend the reach and impact of its immuno-oncology franchise to patients into the next decade. Reblozyl, approved for first-line MDS-associated anemia, continues to drive market share within the larger first-line ring sideroblasts negative population. The CAR-T cell therapy Breyanzi is approved to treat the broadest array of B-cell malignancies. BMY has also been active on the acquisition front to expand its oncology portfolio/pipeline. In 2024, BMY acquired Mirati, a commercial-stage targeted oncology company, obtaining the rights to commercialize lung cancer medicine Krazati and to further develop several clinical assets, including PRMT5 Inhibitor. Krazati, a KRAS inhibitor, is approved for second-line non-small cell lung cancer (NSCLC) and is in clinical development with a PD-1 inhibitor for first-line NSCLC. It is also FDA approved for advanced or metastatic KRAS-mutated colorectal cancer with cetuximab. In addition, PRMT5 Inhibitor is a potential first-in-class MTA-cooperative PRMT5 inhibitor, which is advancing to the next stage of development. The acquisition of RayzeBio, a leader in the field of radiopharmaceuticals for solid tumor oncology, provided BMY with RYZ101, a late-stage asset, an investigational new drug engine and in-house manufacturing capabilities. In 2022, BMY acquired Turning Point and added lead asset, repotrectinib, and other clinical and pre-clinical stage assets to its pipeline. Repotrectinib was approved by the FDA in November 2023 and is marketed under the brand name Augtyro. Augtyro, a kinase inhibitor, is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. It is also intended for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. Bristol Myers is also focused on developing drugs with presence in hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. A Look at Estimates: PFE vs BMY The Zacks Consensus Estimate for PFE's 2025 sales implies a year-over-year decrease of 0.6%, and that for earnings per share (EPS) suggests a year-over-year decline of 1.61%. EPS estimates for 2025 and 2026 have moved north in the past 60 days. PFE's Estimate Movement The Zacks Consensus Estimate for BMY's 2025 sales implies a year-over-year decrease of 4.13% while that for EPS suggests an increase of 487.83%. The extraordinary EPS growth rate is attributed to an extremely low EPS figure in 2024 due to acquisition expenses. EPS estimates for both 2025 and 2026 have moved south in the past 60 days. BMY's Estimate Movement Price Performance and Valuation of PFE and BMY From a price-performance perspective, PFE has performed better than BMY so far this year. Shares of PFE have declined 6.8%, while those of BMY have lost 15.4%. The large-cap pharma industry has declined 0.3% in the said period. From a valuation standpoint, we use the P/E ratio of the large-cap pharma industry to compare these companies. Going by the same, PFE is slightly more expensive than BMY. PFE's shares currently trade at 7.77X forward earnings, higher than 7.22 for BMY. PFE and BMY's attractive dividend yield is a strong positive for investors. However, PFE's dividend yield of 7.2% is higher than BMY's 5.29%. Which Stock Is a Better Pick for Now? Large pharma/biotech companies are generally considered safe havens for investors interested in this sector. However, with both PFE and BMY stocks currently carrying a Zacks Rank #3 (Hold), choosing one over the other is a complex task. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. PFE has a strong and diverse portfolio but faces challenges like declining sales of its COVID-19 products and U.S. Medicare Part D headwinds in 2025. Several of its key products face patent expirations. Nonetheless, drugs like Vyndaqel, Padcev and Eliquis, and newly acquired products should continue to drive top-line growth. BMY's efforts to revive the top line in the face of generic challenges for key drugs are commendable. However, we believe there is still time before the efforts reap harvest for the company. The outlook for 2025 indicates challenges as of now. Hence, PFE is a better pick at present (despite its slightly pricey valuation), primarily due to the diversity of its portfolio and higher dividend yield compared to BMY. Zacks Names #1 Semiconductor Stock It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report
